Brokerages Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target at $21.21

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $21.21.

MRNS has been the topic of several analyst reports. Royal Bank of Canada reiterated an "outperform" rating and set a $24.00 target price on shares of Marinus Pharmaceuticals in a report on Wednesday, March 6th. StockNews.com downgraded Marinus Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, March 6th. Oppenheimer restated a "market perform" rating and set a $9.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. Finally, HC Wainwright reiterated a "buy" rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, March 26th.

Marinus Pharmaceuticals Stock Up 5.1 %

NASDAQ MRNS traded up $0.40 during trading on Monday, hitting $8.20. The stock had a trading volume of 688,720 shares, compared to its average volume of 449,663. Marinus Pharmaceuticals has a 12 month low of $5.57 and a 12 month high of $11.26. The company has a debt-to-equity ratio of 5.68, a quick ratio of 4.01 and a current ratio of 4.07. The company's 50-day moving average price is $9.43 and its two-hundred day moving average price is $8.57. The company has a market capitalization of $450.43 million, a PE ratio of -2.97 and a beta of 0.91.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. The business had revenue of $7.19 million during the quarter, compared to the consensus estimate of $7.78 million. During the same period in the prior year, the firm earned ($0.76) EPS. As a group, sell-side analysts forecast that Marinus Pharmaceuticals will post -2.43 EPS for the current year.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Eventide Asset Management LLC raised its holdings in Marinus Pharmaceuticals by 42.8% in the 3rd quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company's stock valued at $36,466,000 after acquiring an additional 1,356,800 shares in the last quarter. Lion Point Capital LP raised its holdings in Marinus Pharmaceuticals by 14.6% in the 4th quarter. Lion Point Capital LP now owns 4,222,648 shares of the biopharmaceutical company's stock valued at $21,480,000 after acquiring an additional 538,026 shares in the last quarter. BlackRock Inc. raised its holdings in Marinus Pharmaceuticals by 245.4% in the 2nd quarter. BlackRock Inc. now owns 3,897,770 shares of the biopharmaceutical company's stock valued at $42,330,000 after acquiring an additional 2,769,357 shares in the last quarter. Franklin Resources Inc. raised its holdings in Marinus Pharmaceuticals by 1.3% in the 4th quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company's stock valued at $41,675,000 after acquiring an additional 49,589 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Marinus Pharmaceuticals in the 4th quarter valued at $13,990,000. 98.80% of the stock is owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.